Mark Carthy

Mark has 25 years of operating and investment experience in healthcare and technology companies. Mark Carthy co-founded Orion Equity Partners, LLC in 2008. Orion invests in and advises commercial real estate, biotechnology, and private equity companies. Prior to Orion, Mark joined Oxford Bioscience Partners in 2000 and became General Partner in 2001. Before joining Oxford, he was Biotechnology Portfolio Manager at Morningside Ventures where he focused on early-stage private equity investments. Previously, he was Chief Business Officer of Cubist Pharmaceuticals, where he in-licensed Cubicin, Cubist’s commercial antibiotic that reached annual sales of more than $1 billion in 2014. Prior to Cubist Mark was Senior Director of Business Development at Vertex Pharmaceuticals where he was responsible for collaborations with major pharmaceutical companies. He received his BE in Chemical Engineering from University College Dublin, Ireland, and an MS in Chemical Engineering from the University of Missouri. He received his MBA from Harvard Business School in 1987. Mark was listed on the Forbes 2009 Midas List as a leading venture capitalist.